↓ Skip to main content

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma

Overview of attention for article published in Clinical Sarcoma Research, May 2015
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#32 of 104)
  • Above-average Attention Score compared to outputs of the same age (56th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
Published in
Clinical Sarcoma Research, May 2015
DOI 10.1186/s13569-015-0029-8
Pubmed ID
Authors

Beatrice Seddon, Michelle Scurr, Robin L Jones, Zoe Wood, Cerys Propert-Lewis, Cyril Fisher, Adrienne Flanagan, Jonanthan Sunkersing, Roger A’Hern, Jeremy Whelan, Ian Judson

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 5 19%
Researcher 4 15%
Student > Ph. D. Student 3 11%
Other 3 11%
Student > Doctoral Student 1 4%
Other 0 0%
Unknown 11 41%
Readers by discipline Count As %
Medicine and Dentistry 13 48%
Biochemistry, Genetics and Molecular Biology 1 4%
Agricultural and Biological Sciences 1 4%
Engineering 1 4%
Unknown 11 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2019.
All research outputs
#7,610,760
of 23,205,257 outputs
Outputs from Clinical Sarcoma Research
#32
of 104 outputs
Outputs of similar age
#91,321
of 266,067 outputs
Outputs of similar age from Clinical Sarcoma Research
#2
of 3 outputs
Altmetric has tracked 23,205,257 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 104 research outputs from this source. They receive a mean Attention Score of 3.6. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,067 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.